Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
-To evaluate the efficacy of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg) as assessed by the proportion of subjects achieving sustained virologic response (SVR) at 12 weeks post-treatment (SVR12) (defined as HCV ribonucleic acid [RNA] <lower limit of quantification [LLOQ] 12 weeks after the end of all study therapy). -To evaluate the safety and tolerability of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg).
Inclusion criteria
- Treatment of chronic hepatitis C virus (HCV) infection